Recently occurred keywords included “SCLC”, “irAEs”, “anaplastic lymphoma kinase (ALK)”, “biomarker”, “atezolizumab”, “duvalumab”, “radiomics”, “tumor mutation burden (TMB)”, “tumor burden”, “chemoradiotherapy”, and “microbiome”. This evidence concerns the gene ALK and neoplasm.